Clinical trial recruitment for ABBV-744 study Fundamentals Explained
In Segment C, members will receive ABBV-744 and oral navitoclax. In Section D, participants will obtain ABBV-744 and ruxolitinib. Contributors will obtain treatment until eventually condition progression or maybe the individuals are not able to tolerate the study drugs.For all flow cytometry experiments, ten,000 cells for every replicate ended up a